USE OF THE COMPLEX BETWEEN PROSTATE SPECIFIC ANTIGEN AND ??1-PROTEASE INHIBITOR FOR SCREENING PROSTATE CANCER
- 1 December 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- p. 1956-1960
- https://doi.org/10.1097/00005392-200012000-00021
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron networkUrology, 2000
- European randomized study of prostate cancer screening: first-year results of the Finnish trialBritish Journal of Cancer, 1999
- Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic DiseaseJAMA, 1998
- The European Randomized Study of Screening for Prostate Cancer (ERSPC)British Journal of Urology, 1997
- Usefulness of the ratio free/total prostatespecific antigen in addition to total PSA levels in prostate cancer screeningUrology, 1996
- Evaluation of Percentage of Free Serum Prostate-Specific Antigen to Improve Specificity of Prostate Cancer ScreeningJAMA, 1995
- Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate CancerJournal of Urology, 1993
- Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsinClinical Chemistry, 1991
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology, 1982